Provided by Tiger Fintech (Singapore) Pte. Ltd.

Citius Pharmaceuticals, Inc.

1.29
-0.0800-5.84%
Post-market: 1.290.00000.00%19:29 EDT
Volume:310.95K
Turnover:402.68K
Market Cap:14.42M
PE:-0.22
High:1.33
Open:1.31
Low:1.26
Close:1.37
Loading ...

Citius Oncology Closes $9 Million Offering of Shares, Warrants

MT Newswires Live
·
18 Jul

Citius Oncology Expands Lymphir Distribution With Cencora

MT Newswires Live
·
15 Jul

Citius Oncology Plans Stock Offering; Shares Down

MT Newswires Live
·
14 Jul

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) On The Verge Of Breaking Even

Simply Wall St.
·
11 Jul

Citius Pharmaceuticals Is Maintained at Buy by D. Boral Capital

Dow Jones
·
30 Jun

Citius Oncology On Track to Launch Lymphir in US in H2

MT Newswires Live
·
17 Jun

Citius Oncology expects commercial launch of Lymphir in second half of 2025

TIPRANKS
·
17 Jun

Citius Pharmaceuticals Inc. Announces $15.8 Million Registered Direct Offering to Support LYMPHIR™ Launch

Reuters
·
12 Jun

Citius Pharmaceuticals price target lowered to $6 from $9 at D. Boral Capital

TIPRANKS
·
11 Jun

Top Midday Decliners

MT Newswires Live
·
11 Jun

Citius Pharmaceuticals announces $15.8M registered direct offering

TIPRANKS
·
10 Jun

Citius Pharmaceuticals Inc. Held Special Meeting to Amend Articles of Incorporation

Reuters
·
10 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Copper miners, Chip Stocks, EchoStar

Reuters
·
10 Jun

Citius Pharmaceuticals Is Maintained at Buy by D. Boral Capital

Dow Jones
·
09 Jun

BRIEF-Citius Oncology Enters Into Distribution Services Agreement With Cardinal Health

Reuters
·
09 Jun

Citius Oncology Signs US Distribution Deal With Cardinal Health for Lymphir

MT Newswires Live
·
09 Jun

Citius Pharmaceuticals Inc. Issues $1 Million Promissory Note with 15% Interest Rate, Due December 2025

Reuters
·
04 Jun

Citius Pharmaceuticals Faces Nasdaq Delisting Due to Non-Compliance with Minimum Bid Price Rule

Reuters
·
31 May

Citius Pharmaceuticals Cut to Hold From Buy by Maxim Group

Dow Jones
·
23 May

Citius Pharmaceuticals downgraded to Hold from Buy at Maxim

TIPRANKS
·
23 May